Evaluation of cardiopulmonary and inflammatory markers in dogs with heartworm infection during treatment with the 2014 American Heartworm Society recommended treatment protocol

• Published in: Parasites & vectors 2017-11, Vol.10 (Suppl 2), p.535-535, Article 535
• Main Authors: Yoon, Won-Kyoung, Kim, Ye-Won, Suh, Sang-I L, Choi, Ran, Lee, Seung-Gon, Hyun, Changbaig
• Format: Article
• Language: English
• Subjects: AHS guidelines; Animal shelters; Bioindicators; Biomarker; Biomarkers; C-reactive protein; Calcium-binding protein; Canine heartworm disease; Complications; Coronary artery disease; Cytokines; Dimers; Dirofilaria immitis; Disease; Dogs; Drug therapy; Evaluation; Health aspects; Heart diseases; Heart failure; Heartworm; Infections; Inflammation; Injection; Interleukin 6; Interleukins; Laboratories; Markers; Medical treatment; Melarsomine; Parasitic diseases; Parasitoses; Pesticides; Population; Proteins; Pulmonary arteries; Risk factors; Serum; Serum levels; Thromboembolism; Troponin; Troponin I
• ISSN: 1756-3305; 1756-3305
• DOI: 10.1186/s13071-017-2427-7

Heartworm disease in dogs is a life-threatening parasitic disease. Although adulticide treatment with melarsomine has been proven to be the most effective, complications associated with adulticide treatment are major concerns for clinicians. This study evaluated the change in levels of D-dimer, interleukin-6, C-reactive protein and cardiac troponin I in 12 dogs with different severities of heartworm infection treated by the American Heartworm Society (AHS) recommended protocol during the treatment period. The serum levels of several markers were measured on the day of diagnosis (T-60), before the initiation of melarsomine therapy (T0), 1 day after the first injection (T1), 1 week after the first injection (T7), 1 month after the first injection (T30), 1 day after the second injection (T31), 1 day after the third injection (T32), 1 week after the third injection (T39), 1 month after the third injection (T62), 2 months after the third injection (T92), 3 months after the third injection (T122), and 6 months after the third injection (T182). The serum levels of these markers were significantly different at the test time point after melarsomine treatment and also differed significantly according to the stage of heartworm disease in the dogs. This study found that monitoring of inflammatory and hemostatic markers in dogs with heartworm disease being treated with melarsomine might be beneficial in predicting the clinical outcomes and complications associated with melarsomine treatment.